Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;28(Suppl 1):23S–30S. doi: 10.1111/j.1365-2125.1989.tb03570.x

Xamoterol, a β1-adrenoceptor partial agonist

Review of the clinical efficacy in heart failure

H F Marlow
PMCID: PMC1379873  PMID: 2572251

Abstract

1 Xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587), a β1-adrenoceptor partial agonist, improves both systolic and diastolic function in heart failure patients.

2 Double-blind, randomised studies comparing xamoterol with placebo showed that the beneficial haemodynamic effects of xamoterol produced significant improvements in exercise capacity and symptoms in patients with mild to moderate heart failure. These studies formed the basis for a large European multicentre study programme which recruited over 1000 patients, randomised to xamoterol (200 mg twice daily, n = 617), digoxin (0.125 mg twice daily, n = 135) or placebo (n = 300) for 3 months.

3 Efficacy was assessed by measuring exercise capacity and symptoms. The xamoterol group improved exercise capacity by 37% compared with an 18% improvement in the placebo group. Differences in the symptom scores measured by visual analogue scales and Likert scores indicated significant improvements by xamoterol in the cardinal symptoms of heart failure, dyspnoea and fatigue.

4 Analyses of data from subsets of patients in the study showed that elderly patients, patients on no other heart failure therapy and patients with cardiomegaly all had similar improvements in exercise and symptoms to those seen in the whole study population. In the subset which included digoxin treatment, xamoterol produced significantly greater improvements in exercise capacity than digoxin (33% vs 17%, P < 0.05) and was associated with fewer side-effects.

5 Xamoterol is therefore a promising addition to heart failure therapies currently available.

Keywords: xamoterol, heart failure, partial agonist, β1-adrenoceptor

Full text

PDF
23S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss J., Norell M., Canepa-Anson R., Sutton G., Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987 Jan;57(1):17–22. doi: 10.1136/hrt.57.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhatia S. J., Swedberg K., Chatterjee K. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy. Am Heart J. 1986 Apr;111(4):692–696. doi: 10.1016/0002-8703(86)90101-8. [DOI] [PubMed] [Google Scholar]
  3. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  4. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  5. Detry J. M., Decoster P. M., Buy J. J., Rousseau M. F., Brasseur L. A. Antianginal effects of corwin, a new beta-adrenoceptor partial agonist. Am J Cardiol. 1984 Feb 1;53(4):439–443. doi: 10.1016/0002-9149(84)90009-2. [DOI] [PubMed] [Google Scholar]
  6. Furberg C. D., Yusuf S. Effect of drug therapy on survival in chronic heart failure. Adv Cardiol. 1986;34:124–130. doi: 10.1159/000413045. [DOI] [PubMed] [Google Scholar]
  7. Grossman W., Barry W. H. Diastolic pressure-volume relations in the diseased heart. Fed Proc. 1980 Feb;39(2):148–155. [PubMed] [Google Scholar]
  8. Katz A. M., Smith V. E. Regulation of myocardial function in the normal and diseased heart. Modification by inotropic drugs. Eur Heart J. 1982 Dec;3 (Suppl 500):11–18. [PubMed] [Google Scholar]
  9. Lipkin D. P., Poole-Wilson P. A. Symptoms limiting exercise in chronic heart failure. Br Med J (Clin Res Ed) 1986 Apr 19;292(6527):1030–1031. doi: 10.1136/bmj.292.6527.1030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. MacLennan W. J. Diuretics in the elderly: how safe? Br Med J (Clin Res Ed) 1988 Jun 4;296(6636):1551–1552. doi: 10.1136/bmj.296.6636.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Molajo A. O., Bennett D. H. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J. 1985 Jul;54(1):17–21. doi: 10.1136/hrt.54.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Molajo A. O., Bennett D. H., Marlow H. F., Snow H. M., Bastain W. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease. Br J Clin Pharmacol. 1987 Sep;24(3):373–379. doi: 10.1111/j.1365-2125.1987.tb03183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988 Apr;77(4):721–730. doi: 10.1161/01.cir.77.4.721. [DOI] [PubMed] [Google Scholar]
  15. Pouleur H., van Eyll C., Hanet C., Cheron P., Charlier A. A., Rousseau M. F. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease. Circulation. 1988 May;77(5):1081–1089. doi: 10.1161/01.cir.77.5.1081. [DOI] [PubMed] [Google Scholar]
  16. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  17. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]
  18. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988 Feb 6;1(8580):255–259. doi: 10.1016/s0140-6736(88)90347-9. [DOI] [PubMed] [Google Scholar]
  19. Simonsen S. Haemodynamic effects of ICI 118,587 in cardiomyopathy. Br Heart J. 1984 Jun;51(6):654–657. doi: 10.1136/hrt.51.6.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Soufer R., Wohlgelernter D., Vita N. A., Amuchestegui M., Sostman H. D., Berger H. J., Zaret B. L. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol. 1985 Apr 1;55(8):1032–1036. doi: 10.1016/0002-9149(85)90741-6. [DOI] [PubMed] [Google Scholar]
  21. von Olshausen K. Xamoterol in heart failure. Lancet. 1988 May 21;1(8595):1162–1162. doi: 10.1016/s0140-6736(88)91971-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES